MX387339B - Administración de gamma hidroxibutirato con transportadores de monocarboxilato. - Google Patents

Administración de gamma hidroxibutirato con transportadores de monocarboxilato.

Info

Publication number
MX387339B
MX387339B MX2015011242A MX2015011242A MX387339B MX 387339 B MX387339 B MX 387339B MX 2015011242 A MX2015011242 A MX 2015011242A MX 2015011242 A MX2015011242 A MX 2015011242A MX 387339 B MX387339 B MX 387339B
Authority
MX
Mexico
Prior art keywords
administration
ghb
discovered
gamma hydroxybutyrate
monocarboxylate transporters
Prior art date
Application number
MX2015011242A
Other languages
English (en)
Other versions
MX2015011242A (es
Inventor
Mark Eller
Original Assignee
Jazz Pharmaceuticals Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51031733&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX387339(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jazz Pharmaceuticals Ireland Ltd filed Critical Jazz Pharmaceuticals Ireland Ltd
Publication of MX2015011242A publication Critical patent/MX2015011242A/es
Publication of MX387339B publication Critical patent/MX387339B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Medical Informatics (AREA)
  • Primary Health Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Toxicology (AREA)

Abstract

Una modalidad de la presente invención es para mejorar la seguridad y eficacia de la administración de GHB o una sal del mismo a un paciente. Se ha descubierto que la administración concomitante de un inhibidor de MCT, tales como diclofenaco, valproato, o ibuprofeno, afectará la administración de GHB. Por ejemplo, se ha descubierto que el diclofenaco reduce el efecto de GHB en el cuerpo, causando potencialmente una condición insegura. Adicionalmente, se ha descubierto que el valproato aumenta el efecto de GHB en el cuerpo, causando potencialmente una condición insegura.
MX2015011242A 2013-03-01 2014-02-28 Administración de gamma hidroxibutirato con transportadores de monocarboxilato. MX387339B (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201361771557P 2013-03-01 2013-03-01
US201361777873P 2013-03-12 2013-03-12
US13/837,714 US9050302B2 (en) 2013-03-01 2013-03-15 Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
US13/872,997 US8772306B1 (en) 2013-03-01 2013-04-29 Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
US13/873,000 US8952029B2 (en) 2013-03-01 2013-04-29 Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
PCT/US2014/019217 WO2014134380A1 (en) 2013-03-01 2014-02-28 Administration of gamma hydroxybutyrate with monocarboxylate transporters

Publications (2)

Publication Number Publication Date
MX2015011242A MX2015011242A (es) 2016-05-31
MX387339B true MX387339B (es) 2025-03-18

Family

ID=51031733

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011242A MX387339B (es) 2013-03-01 2014-02-28 Administración de gamma hidroxibutirato con transportadores de monocarboxilato.

Country Status (21)

Country Link
US (10) US9050302B2 (es)
EP (3) EP3695833A1 (es)
JP (1) JP6433440B2 (es)
KR (1) KR102239042B1 (es)
CN (2) CN111317730A (es)
AU (1) AU2014223373B2 (es)
BR (1) BR112015021012A8 (es)
CA (1) CA2902948C (es)
CY (2) CY1120086T1 (es)
DK (2) DK3335708T3 (es)
ES (2) ES2659284T3 (es)
HR (1) HRP20200215T1 (es)
IL (1) IL240874B (es)
LT (1) LT3335708T (es)
MX (1) MX387339B (es)
PL (2) PL3335708T3 (es)
PT (2) PT3335708T (es)
SG (1) SG11201505029QA (es)
SI (1) SI3335708T1 (es)
TW (1) TWI619492B (es)
WO (1) WO2014134380A1 (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
NZ573360A (en) 2006-05-04 2012-08-31 Boehringer Ingelheim Int Polymorphic forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
KR20200118243A (ko) * 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
AU2010323068B2 (en) 2009-11-27 2015-09-03 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
US20120076865A1 (en) 2010-03-24 2012-03-29 Jazz Pharmaceuticals, Inc. Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
KR101927068B1 (ko) 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
EP2849754B1 (en) 2012-05-14 2022-09-14 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
US8591922B1 (en) 2012-12-14 2013-11-26 Jazz Pharmacuticals, Inc. Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
US9050302B2 (en) 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
CN113061089A (zh) 2015-09-23 2021-07-02 凯瑞康宁生物工程（武汉）有限公司 γ-羟基丁酸的前药及其组合物和用途
JP2019517542A (ja) 2016-06-10 2019-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング リナグリプチンおよびメトホルミンの組合せ
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11000498B2 (en) 2016-07-22 2021-05-11 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
JP7219213B2 (ja) 2016-09-06 2023-02-07 ジャズ ファーマスティカルズ アイルランド リミテッド （ｒ）－２－アミノ－３－フェニルプロピルカルバメートの溶媒和物フォーム
EP4316592A3 (en) 2016-10-06 2024-05-01 Axsome Malta Ltd. Carbamoyl phenylalaninol compounds and uses thereof
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
US10959976B2 (en) 2017-06-02 2021-03-30 Jazz Pharmaceuticals Ireland Limited Methods and compositions for treating excessive sleepiness
EP3661911A4 (en) 2017-07-31 2021-04-14 Jazz Pharmaceuticals Ireland Limited CARBAMOYL-PHENYLALANINOL ANALOGS AND USES THEREOF
KR20200053570A (ko) * 2017-09-12 2020-05-18 오비드 테라퓨틱스 인크. 기면증의 치료에서 가복사돌의 사용
KR20210094513A (ko) 2018-11-19 2021-07-29 재즈 파마슈티칼즈 아일랜드 리미티드 알코올-내성 약물 제형
CN113473980A (zh) 2019-03-01 2021-10-01 弗拉梅尔爱尔兰有限公司 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物
JP7709202B2 (ja) * 2019-06-28 2025-07-16 ユニバーシティ オブ コペンハーゲン 睡眠障害を伴うｃｎｓ障害の治療
US20210186907A1 (en) * 2019-12-24 2021-06-24 Jazz Pharmaceuticals Ireland Limited Ghb dosing
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
EP4135680A1 (en) * 2020-04-16 2023-02-22 Flamel Ireland Limited Methods of administering gamma-hydroxybutyrate compositions with divalproex sodium
US20220040128A1 (en) * 2020-04-16 2022-02-10 Flamel Ireland Limited Methods of administering gamma-hydroxybutyrate compositions with divalproex sodium
KR20230011359A (ko) 2020-06-18 2023-01-20 엑스더블유파마 리미티드 수용성 활성 약제 성분의 제어 방출 과립화물
US11896573B2 (en) 2020-07-24 2024-02-13 XWPharma Ltd. Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative
JP7751638B2 (ja) 2020-10-05 2025-10-08 エックスダブリューファーマ リミテッド ガンマ－ヒドロキシ酪酸誘導体の調節放出組成物
US20230404950A1 (en) 2020-10-08 2023-12-21 Jazz Pharmaceuticals Ireland Limited Sodium oxybate to treat idiopathic hypersomnia
WO2022082105A2 (en) 2020-10-16 2022-04-21 Jazz Pharmaceuticals Ireland Limited Treatment methods using ghb
DK4308086T3 (da) 2021-03-19 2025-11-17 Xwpharma Ltd Farmakokinetik af formuleringer med kombineret frigivelse af et gamma-hydroxysmørsyrederivat
EP4415701A1 (en) 2021-10-11 2024-08-21 Jazz Pharmaceuticals Ireland Limited Method of administering oxybate
US20250073191A1 (en) 2022-01-11 2025-03-06 Jazz Pharmaceuticals Ireland Limited Method of administering oxybate
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
EP4658242A1 (en) 2023-02-03 2025-12-10 Tris Pharma, Inc. Low sodium oxybate once nightly composition
AU2024278948A1 (en) 2023-05-30 2025-12-11 Axsome Therapeutics, Inc. Solriamfetol for treating cognitive impairment in a subject with impaired cognition associated with obstructive sleep apnea and excessive daytime sleepiness
WO2025006965A1 (en) 2023-06-29 2025-01-02 Axsome Therapeutics, Inc. Methods of administering solriamfetol to lactating women

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE237309C (es)
US797171A (en) 1904-08-04 1905-08-15 Antonio Cerruti Fruit-washer.
US3051619A (en) 1960-05-19 1962-08-28 Equilibre Biolog L 4-hydroxy butyric acid therapeutic compositions and process of use for clinical sedation, hypnosis, or anaesthesia
GB922029A (en) 1960-05-19 1963-03-27 Equilibre Biolog L Therapeutic composition
GB971700A (en) 1961-02-02 1964-09-30 Boots Pure Drug Co Ltd Anti-Inflammatory Agents
FR2442M (fr) 1962-10-17 1964-04-06 Henry Eugene L'acide dipropylacétique et ses dérivés en tant que nouveuax médicaments dépresseurs du systeme nerveux central.
FR2383920A1 (fr) 1977-03-15 1978-10-13 Labaz Procede de preparation d'un derive d'acetonitrile et derive obtenu par ce procede
US4155929A (en) 1977-05-25 1979-05-22 Labaz Process for the preparation of an acetonitrile derivative
EP0044801B1 (de) 1980-07-17 1984-02-15 Josef Dr. Klosa Nichthygroskopische Salze der 4-Hydroxybuttersäure, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung pharmazeutischer Mittel
JPS61186319A (ja) * 1985-02-12 1986-08-20 Res Dev Corp Of Japan 睡眠覚醒調節剤
DD237309A1 (de) 1985-05-15 1986-07-09 Berlin Chemie Veb Verfahren zur herstellung eines lagerstabilen natriumsalzes der gamma-hydroxybuttersaeure
IT1217783B (it) 1988-06-03 1990-03-30 Farmaceutico Ct S R L Lab Impiego di salo dell,acido gamma idrossi butirrico per la preparazione di composizioni farmaceutiche adatta ad essereimpiegate nella terapia dell,alcolismo e composizioni relative
US4983612A (en) 1989-10-05 1991-01-08 American Home Products Corporation Antihypertensive benzopyran derivatives
DE4113984C2 (de) 1991-04-29 2002-05-08 Koehler Chemie Dr Franz Salze der 4-Hydroxy-Buttersäure
IT1271403B (it) 1993-03-26 1997-05-28 Ct Lab Farm Srl Sali dell'acido gamma-idrossibutirrico ad attivita' ansiolitica e per il trattamento degli stati depressivi
US5833599A (en) 1993-12-13 1998-11-10 Multum Information Services Providing patient-specific drug information
US5762955A (en) 1994-02-04 1998-06-09 Smith; Stephen Jay Method for application and maintenance of medication on body tissue
US7072840B1 (en) 1994-10-28 2006-07-04 Cybear, L.L.C. Prescription management system
US5845255A (en) 1994-10-28 1998-12-01 Advanced Health Med-E-Systems Corporation Prescription management system
US5758095A (en) 1995-02-24 1998-05-26 Albaum; David Interactive medication ordering system
US6112182A (en) 1996-01-16 2000-08-29 Healthcare Computer Corporation Method and apparatus for integrated management of pharmaceutical and healthcare services
US5990162A (en) 1997-08-29 1999-11-23 Orphan Medical, Inc. Method for treatment of fibromyalgia and chronic fatigue syndrome
US6014631A (en) 1998-04-02 2000-01-11 Merck-Medco Managed Care, Llc Computer implemented patient medication review system and process for the managed care, health care and/or pharmacy industry
JP4374441B2 (ja) 1998-12-23 2009-12-02 ジェイピーアイ コマーシャル，リミティド ライアビリティ カンパニー 睡眠発作治療のための、ガンマ−ヒドロキシ酪酸塩の微生物的に安全で安定な液剤
US6067524A (en) 1999-01-07 2000-05-23 Catalina Marketing International, Inc. Method and system for automatically generating advisory information for pharmacy patients along with normally transmitted data
US6204245B1 (en) * 1999-09-17 2001-03-20 The Regents Of The University Of California Treatment of narcolepsy with immunosuppressants
US6383764B1 (en) * 2000-04-28 2002-05-07 The Regents Of The University Of California Methods of identifying compounds for controlling absence seizures in a mammal relating to prolactin-releasing peptide(PrRP)
ES2383673T3 (es) 2000-09-22 2012-06-25 Jpi Commercial, Llc Composiciones de gamma-hidroxibutirato que contienen portadores de hidrato de carbonos
US6315720B1 (en) * 2000-10-23 2001-11-13 Celgene Corporation Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US7668730B2 (en) 2002-12-17 2010-02-23 JPI Commercial, LLC. Sensitive drug distribution system and method
RU2232012C1 (ru) 2003-06-02 2004-07-10 Иркутский государственный медицинский университет Способ лечения бруксизма
US20110237664A1 (en) * 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
US20090137565A1 (en) 2004-11-10 2009-05-28 The Trustees Of Columbia University In The City Of New York Method for treatment of movement disorders
US20110145018A1 (en) * 2005-03-21 2011-06-16 Fotsch Edward J Drug and medical device safety and support information reporting system, processing device and method
US20080293698A1 (en) * 2005-05-16 2008-11-27 Joseph Johnson Methods and Compositions for Treating Arg
US8889635B2 (en) 2008-09-30 2014-11-18 The Regents Of The University Of Michigan Dendrimer conjugates
US8771735B2 (en) 2008-11-04 2014-07-08 Jazz Pharmaceuticals, Inc. Immediate release dosage forms of sodium oxybate
FR2938431B1 (fr) * 2008-11-14 2013-12-20 Debregeas Et Associes Pharma Nouvelle composition a base d'acide gamma-hydroxybutyrique
US20120076865A1 (en) 2010-03-24 2012-03-29 Jazz Pharmaceuticals, Inc. Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
AU2010352575C1 (en) 2010-05-04 2016-11-10 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
JP2013540748A (ja) 2010-09-16 2013-11-07 コーネル ユニバーシティー 血液脳関門の透過性を調節するためのアデノシン受容体シグナル伝達の使用法
US8591922B1 (en) 2012-12-14 2013-11-26 Jazz Pharmacuticals, Inc. Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
US9050302B2 (en) 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters

Also Published As

Publication number Publication date
TW201511752A (zh) 2015-04-01
KR102239042B1 (ko) 2021-04-12
EP2961399B1 (en) 2017-11-15
DK2961399T3 (en) 2018-02-19
IL240874B (en) 2019-06-30
US20210212970A1 (en) 2021-07-15
US20210128502A1 (en) 2021-05-06
US8772306B1 (en) 2014-07-08
US11986446B2 (en) 2024-05-21
HK1215539A1 (en) 2016-09-02
KR20150125943A (ko) 2015-11-10
PT2961399T (pt) 2018-02-21
CY1120086T1 (el) 2018-12-12
CN105073106A (zh) 2015-11-18
BR112015021012A8 (pt) 2019-11-26
HK1256965A1 (en) 2019-10-04
US20190274980A1 (en) 2019-09-12
PT3335708T (pt) 2020-03-17
WO2014134380A1 (en) 2014-09-04
MX2015011242A (es) 2016-05-31
US20220193015A1 (en) 2022-06-23
AU2014223373B2 (en) 2018-12-06
LT3335708T (lt) 2020-05-11
US20140249222A1 (en) 2014-09-04
CA2902948C (en) 2019-12-31
EP2961399A1 (en) 2016-01-06
TWI619492B (zh) 2018-04-01
CN111317730A (zh) 2020-06-23
US9050302B2 (en) 2015-06-09
US20170049731A1 (en) 2017-02-23
US8952029B2 (en) 2015-02-10
PL2961399T3 (pl) 2018-05-30
US10864181B2 (en) 2020-12-15
US10213400B2 (en) 2019-02-26
BR112015021012A2 (pt) 2017-07-18
US20140249115A1 (en) 2014-09-04
EP3335708B1 (en) 2019-12-11
CA2902948A1 (en) 2014-09-04
US20160015662A1 (en) 2016-01-21
IL240874A0 (en) 2015-10-29
ES2659284T3 (es) 2018-03-14
AU2014223373A1 (en) 2015-08-20
HRP20200215T1 (hr) 2020-05-15
CY1122992T1 (el) 2021-10-29
JP2016510031A (ja) 2016-04-04
DK3335708T3 (da) 2020-02-24
PL3335708T3 (pl) 2020-08-24
US11253494B2 (en) 2022-02-22
SG11201505029QA (en) 2015-07-30
SI3335708T1 (sl) 2020-04-30
US9486426B2 (en) 2016-11-08
EP3695833A1 (en) 2020-08-19
ES2775779T3 (es) 2020-07-28
EP3335708A1 (en) 2018-06-20
JP6433440B2 (ja) 2018-12-05
US20180200210A1 (en) 2018-07-19

Similar Documents

Publication Publication Date Title
MX387339B (es) Administración de gamma hidroxibutirato con transportadores de monocarboxilato.
BR112016028643A2 (pt) ?dispositivo de vedação e sistema de entrega?
CY1122796T1 (el) Βελτιωμενες φαρμακοτεχνικες μορφες αδενοϊων
MX2019009853A (es) Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres.
BR112016014410A2 (pt) terapia de combinação com vacina de neoantígeno
MX2017015236A (es) Beneficios de la suplementacion con n-acetilcisteina y glicina para mejorar los niveles de glutation.
MX2018015352A (es) Subtipos de receptores y compuestos retinoides y rexinoides de funcion selectiva combinados con moduladores inmunitarios para inmunoterapia contra el cancer.
CR20160308A (es) Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores
MX2017000307A (es) Tratamiento de leucemia con inhibidores de histona deacetilasa.
CR20170219A (es) Inhibidores del bromodominio
BR112017010442A2 (pt) produto farmacêutico, usos de uma seringa de polímero, de um composto sequestrante de oxigênio, e de uma solução de imunoglobulina
MX2015014713A (es) Uso de una composicion que comprende aceite de pescado y jugo para el tratamiento y/o postratamiento de cancer.
BR112016008736A2 (pt) formulação estável de insulina glulisina
BR112018003178A2 (pt) absorvente feminino com braçadeiras de barreira
CL2015002180A1 (es) Terapia de combinación para el tratamiento de neumonía nosocomial
CY1122899T1 (el) Υδατικη συσταση περιλαμβανουσα παρακεταμολη και ιβουπροφαινη
CL2015003343A1 (es) Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico.
BR112016015851A2 (pt) Formulações farmacêuticas estabilizadas de insulina aspart
PH12016500356A1 (en) Nsaid and sigma receptor ligand combinations
EA201691171A1 (ru) Композиция, применимая для активации женской репродуктивной способности
CL2015002253A1 (es) Composiciones farmacéuticas para el tratamiento de la helicobacter pylori.
CO7170174A2 (es) Formulación farmacéutica
BR112016012248A2 (pt) método de tratamento de nefropatia
CR20160353A (es) Inhibidor de proteína de transferencia del éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden el inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
NZ713440A (en) Nsaid administration and related compositions, methods and systems.